FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1. PMID 37146754 · J Thorac Oncol · 2023-Aug 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Endoscopic management of low output recurrent colonic fistula or leak after anterior resection for rectal cancer: a randomized controlled trial. PMID 37145174 · Surg Endosc · 2023-Aug 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Larotrectinib versus historical standard of care in patients with infantile fibrosarcoma: protocol of EPI-VITRAKVI. PMID 37133249 · Future Oncol · 2023-Aug 未发现恶性肿瘤人群证据。 |
B
|
仅广召回影子组 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| EUS-Guided Choledocho-duodenostomy Using Lumen Apposing Stent Versus ERCP With Covered Metallic Stents in Patients With Unresectable Malignant Distal Biliary Obstruction: A Multicenter Randomized Controlled Trial (DRA-MBO Trial). PMID 37121331 · Gastroenterology · 2023-Aug 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Immune Reconstitution Profiling Suggests Antiviral Protection after Transplantation with Omidubicel: A Phase 3 Substudy. PMID 37120136 · Transplant Cell Ther · 2023-Aug This is a substudy of a Phase 3 randomized trial evaluating omidubicel (an advanced cell therapy, not a drug) for allogeneic hematopoietic cell transplantation. While it is an oncology-related human randomized Phase 3 trial, it does not meet the criteria for a drug-containing intervention or a primary/key secondary time-to-event efficacy endpoint. The study focuses on immune reconstitution kinetics and their correlation with infection rates, not on a time-to-event efficacy endpoint like OS, PFS, DFS, etc. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Hypotension Prediction Index guided Goal Directed therapy and the amount of Hypotension during Major Gynaecologic Oncologic Surgery: a Randomized Controlled clinical Trial. PMID 37119322 · J Clin Monit Comput · 2023-Aug The record is an oncology randomized controlled trial in humans, but it does not involve a drug-containing intervention (the interventions are a machine learning algorithm for hypotension prediction and a goal-directed therapy protocol) and the primary outcome is a measure of intraoperative hypotension, not a time-to-event efficacy endpoint like OS or PFS. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension. PMID 37103755 · J Neurol · 2023-Aug 未发现恶性肿瘤人群证据。 |
H
B
|
仅广召回影子组 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Immunoreactivity to WT1 peptide vaccine is associated with prognosis in elderly patients with acute myeloid leukemia: follow-up study of randomized phase II trial of OCV-501, an HLA class II-binding WT1 polypeptide. PMID 37093243 · Cancer Immunol Immunother · 2023-Aug 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Sintilimab Plus Modified FOLFIRINOX in Metastatic or Recurrent Pancreatic Cancer: The Randomized Phase II CISPD3 Trial. PMID 37052821 · Ann Surg Oncol · 2023-Aug 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Re: Pain and Health-related Quality of Life with Olaparib Versus Physician's Choice of Next-generation Hormonal Drug in Patients with Metastatic Castration-resistant Prostate Cancer with Homologous Recombination Repair Gene Alterations (PROfound): An Open-label, Randomised, Phase 3 Trial. PMID 37032188 · Eur Urol · 2023-Aug 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Construct validity and responsiveness of a health-related symptom index for persons either treated or monitored for anal high-grade squamous intraepithelial lesions (HSIL): AMC-A01/-A03. PMID 37020153 · Qual Life Res · 2023-Aug This publication is from a Phase III randomized oncology trial, but it is a validation study for a patient-reported outcome instrument, not an efficacy report with a time-to-event endpoint (like OS, PFS, DFS) or drug intervention results. Therefore, it does not meet the criteria for inclusion in the Kaplan-Meier digitization cohort. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Sumac-rose water mouthwash versus benzydamine to prevent radiation-induced oral mucositis in head and neck cancers: a phase II randomized trial. PMID 36947237 · J Cancer Res Clin Oncol · 2023-Aug 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Measuring Frailty Using Patient-Reported Outcomes (PRO) Data: A Feasibility Study in Patients with Multiple Myeloma. PMID 36935467 · Qual Life Res · 2023-Aug The record is a feasibility/methodological study analyzing pooled data from previous trials to develop a patient-reported frailty scale. It is not an original report of a randomized clinical trial's efficacy results. It does not present time-to-event data (OS, PFS, etc.) or Kaplan-Meier curves for a drug intervention. It is a retrospective, secondary analysis focused on measurement properties of a PRO-based frailty phenotype. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Suprapapillary placement of plastic versus metal stents for malignant biliary hilar obstructions: a multicenter, randomized trial. PMID 36907528 · Gastrointest Endosc · 2023-Aug 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Analysis of Prognostic Factors and Surgical Management of Elderly Patients with Low-Grade Gliomas. PMID 36858293 · World Neurosurg · 2023-Aug The study is a retrospective analysis of a SEER database to develop a prognostic nomogram. Although it is oncology, human, and uses time-to-event endpoints, it is not a report of a randomized Phase II/III or III trial testing a drug intervention. The 'randomized' designation refers to random splitting of the dataset into training/test sets, not to a clinical trial randomization. The drug (chemotherapy) is listed as a covariate, not as an interventional arm. Therefore, it does not meet the criteria for inclusion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Based on ARASENS trial: efficacy and safety of darolutamide as an emerging option of endocrinotherapy for metastatic hormone-sensitive prostate cancer-an updated systematic review and network meta-analysis. PMID 36856851 · J Cancer Res Clin Oncol · 2023-Aug 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Somatostatin-analog effect on pancreatic fistula after radical gastrectomy: a pilot randomized controlled trial. PMID 36745222 · J Cancer Res Clin Oncol · 2023-Aug The study is a randomized controlled trial in the oncology setting (gastric cancer surgery) with a drug intervention, but it is not a Phase III/IIIb or Phase II/III trial (it's a pilot study). The primary endpoint is the incidence of postoperative pancreatic fistula, a safety/complication endpoint, not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS) with Kaplan-Meier or HR. Therefore, it does not meet the required criteria for inclusion in the cohort. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Effects of Preoperative Oral Carbohydrate Electrolyte Drinks on Preoperative Hypokalemia Incidence in Patients Scheduled for Laparoscopic Colorectal Resection: A Three-Arm Randomized Clinical Trial. PMID 36732123 · J Perianesth Nurs · 2023-Aug 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Randomised clinical trial to test the phenolization in sacrococcygeal pilonidal disease. PMID 36700412 · Int Wound J · 2023-Aug 未发现恶性肿瘤人群证据。 |
B
|
仅广召回影子组 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| A preoperative scoring system to predict lymph node metastasis in intrahepatic cholangiocarcinoma. PMID 36689090 · Hepatol Int · 2023-Aug The study is a retrospective, multi-institutional analysis developing a preoperative scoring system for lymph node metastasis in intrahepatic cholangiocarcinoma. It is randomized (for cohort allocation), involves a time-to-event endpoint (overall survival), and reports original results. However, it lacks a drug-containing intervention (it is a diagnostic/predictive model study) and does not establish a Phase III or Phase II/III trial phase. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Using deep learning to predict survival outcome in non-surgical cervical cancer patients based on pathological images. PMID 36653539 · J Cancer Res Clin Oncol · 2023-Aug The record is an original retrospective cohort study, not a randomized trial of a specific drug intervention. While it reports OS and Kaplan-Meier curves, it does not meet the core criteria of being a Phase III/IIIb or Phase II/III randomized trial with a drug-containing intervention as the experimental variable. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Predictive value on advance hodgkin lymphoma treatment outcome of end-of treatment FDG PET/CT in the HD0607 clinical trial. PMID 36534947 · Hematol Oncol · 2023-Aug The record is from a randomized trial (HD0607) with a drug intervention and a primary PFS endpoint, and it presents original results. However, the phase of the trial (Phase III/IIIb or Phase II/III) is not explicitly stated in the provided metadata or abstract. The deterministic review flagged phase as unclear. Therefore, while all other criteria are met, the phase cannot be established, making eligibility indeterminate. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Impact of physical activity on postural stability and coordination in children with posterior fossa tumor: randomized control phase III trial. PMID 36525069 · J Cancer Res Clin Oncol · 2023-Aug The study is a randomized Phase III trial in an oncology population (children with posterior fossa tumors), but it does not meet the core eligibility criteria: the interventions are non-drug physical therapy programs (Pilates, balance training, coordination exercises), and the primary outcomes are functional measures of postural stability and coordination, not time-to-event efficacy endpoints. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| FOCUS4 biomarker laboratories: from the benefits to the practical and logistical issues faced during 6 years of centralised testing. PMID 35256486 · J Clin Pathol · 2023-Aug The record describes a biomarker laboratory experience within the FOCUS4 trial. While the trial is Phase II/III and randomized, the abstract does not report any trial efficacy results (e.g., OS, PFS, HR) and focuses solely on biomarker testing logistics and performance. There is no mention of a drug intervention or its efficacy. Therefore, it does not meet the criteria for a primary result report of a drug-containing randomized trial with a time-to-event endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Phase III study of the European Organisation for Research and Treatment of Cancer Quality of Life cancer survivorship core questionnaire. PMID 35088246 · J Cancer Surviv · 2023-Aug The record describes a Phase III questionnaire development study, not a randomized therapeutic trial. It evaluates a quality-of-life instrument for cancer survivors, not a drug intervention. There is no time-to-event efficacy endpoint (OS, PFS, etc.) and it is not a report of a clinical trial outcome. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Use of machine learning-based integration to develop an immune-related signature for improving prognosis in patients with gastric cancer. PMID 37120631 · Sci Rep · 2023-Apr-29 The record describes a bioinformatics and prognostic signature development study in gastric cancer patients, not a clinical trial. It lacks clear identification of a Phase III/IIIb or Phase II/III randomized trial, a drug-containing intervention in a trial context, and explicit time-to-event efficacy endpoints like OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR. The publication types include 'Randomized Controlled Trial' and 'Journal Article', but the content does not match a clinical trial report. The study is a prognostic biomarker analysis using public datasets and machine learning, not an interventional drug trial. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial. PMID 37120593 · J Hematol Oncol · 2023-Apr-29 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Radiotherapy-Dose Escalated for Large Volume Primary Tumors-And Cetuximab with or without Induction Chemotherapy for HPV Associated Squamous Cell Carcinoma of the Head and Neck-A Randomized Phase II Trial. PMID 37174008 · Cancers (Basel) · 2023-Apr-28 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. PMID 36912538 · N Engl J Med · 2023-Apr-27 The trial is a randomized oncology study with definitive (Phase III) status and reports original results, but it does not meet all required criteria. The intervention arms do not contain a drug (monitoring vs. surgery vs. radiotherapy), and the abstract does not provide Kaplan-Meier curves, hazard ratios, or other explicit time-to-event statistical analyses for the primary or secondary endpoints. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Comprehensive workplace intervention for cancer prevention in China (WECAN): protocol for a stepped-wedge, cluster-randomised controlled trial. PMID 37185182 · BMJ Open · 2023-Apr-25 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Nutri-PEITC Jelly Significantly Improves Progression-Free Survival and Quality of Life in Patients with Advanced Oral and Oropharyngeal Cancer: A Blinded Randomized Placebo-Controlled Trial. PMID 37175527 · Int J Mol Sci · 2023-Apr-25 The trial is randomized and reports PFS (a time-to-event endpoint) in oncology patients, but it does not involve a drug-containing intervention (Nutri-PEITC Jelly is a fortified diet/supplement, not a standard oncology drug). Furthermore, the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| An Update on Recent Advances of Photodynamic Therapy for Primary Cutaneous Lymphomas. PMID 37242570 · Pharmaceutics · 2023-Apr-24 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Individualised perioperative blood pressure and fluid therapy in oesophagectomy – study protocol for a randomised clinical trial. PMID 37125828 · Dan Med J · 2023-Apr-24 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| In silico cancer immunotherapy trials uncover the consequences of therapy-specific response patterns for clinical trial design and outcome. PMID 37095077 · Nat Commun · 2023-Apr-24 The record describes a computer simulation study using mathematical models to explore clinical trial design principles for immunotherapy. It is not an original clinical trial report with human participants, a drug-containing intervention, or a primary time-to-event efficacy endpoint. Therefore, it is excluded. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| [Response characteristics of tislelizumab combined with chemotherapy in first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer]. PMID 37078218 · Zhonghua Zhong Liu Za Zhi · 2023-Apr-23 The report is a secondary analysis of responders from a randomized trial, not the primary or definitive report of the trial's overall efficacy. The trial phase is not explicitly established in the metadata, and the analysis is focused on subgroup characteristics rather than the primary trial outcome. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Anti-inflammatory effect of combining fish oil and evening primrose oil supplementation on breast cancer patients undergoing chemotherapy: a randomized placebo-controlled trial. PMID 37081029 · Sci Rep · 2023-Apr-20 The record reports a randomized, placebo-controlled trial in breast cancer patients receiving chemotherapy. However, it lacks the required time-to-event efficacy endpoint (e.g., OS, PFS, DFS) for inclusion in the Kaplan-Meier digitization cohort. The primary outcomes are changes in inflammatory cytokines and nutritional status, not survival or progression-free survival. The trial phase is not explicitly stated as Phase III or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| [Whey protein and caseinate supplementation in oncological patients undergoing elective surgery for the modification of functional capacity]. PMID 36880717 · Nutr Hosp · 2023-Apr-20 The study is an oncology randomized controlled trial with original results, but it does not meet key eligibility criteria: it lacks a specified Phase III or II/III design, uses nutritional supplements (whey protein, caseinate) rather than a drug intervention, and reports functional/body composition outcomes rather than a time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| When Less Can Be More: How the 10-Year Updated Results From the Randomized Controlled AMAROS Trial Should Affect Axillary Management in the Setting of a Positive Node. PMID 36848617 · J Clin Oncol · 2023-Apr-20 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651. PMID 36473143 · J Clin Oncol · 2023-Apr-20 Explicitly meets all criteria: Phase III randomized trial in human oncology with drug intervention, final results reporting OS and PFS (time-to-event endpoints), and original formal-result report. |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | confirmed 3 Figure · 8 Panel · risk visible |
| Assessing the impact of digital patient monitoring on health outcomes and healthcare resource usage in addition to the feasibility of its combination with at-home treatment, in participants receiving systemic anticancer treatment in clinical practice: protocol for an interventional, open-label, multicountry platform study (ORIGAMA). PMID 37076159 · BMJ Open · 2023-Apr-19 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Angiogenesis inhibitors for the treatment of epithelial ovarian cancer. PMID 37185961 · Cochrane Database Syst Rev · 2023-Apr-18 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| The success of anti-PD-1 with chemotherapy for esophageal squamous cell carcinoma. PMID 37075702 · Cell Rep Med · 2023-Apr-18 The record describes a phase III randomized trial with a drug intervention in oncology. However, the provided metadata does not explicitly mention a time-to-event endpoint, Kaplan-Meier analysis, or hazard ratio, which are required criteria for eligibility. The record cannot be confirmed as a report of a primary or secondary analysis with such an endpoint based solely on the provided text. |
H
L
B
|
旧查询独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Protocol of the optimal study: Optimization of polypharmacy in geriatric oncology - A randomized controlled trial. PMID 37072729 · BMC Cancer · 2023-Apr-18 This is a randomized oncology trial protocol, but it does not meet the core eligibility criteria: the primary endpoint is quality of life, not a time-to-event efficacy endpoint. The report is a protocol without results, and the intervention is a medication review process rather than a direct drug administration. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE. PMID 36779348 · Circulation · 2023-Apr-18 The study is a randomized, placebo-controlled cardiovascular outcomes trial (FOURIER) and its open-label extension, focusing on LDL-C levels and cardiovascular/safety outcomes. It is not an oncology trial, and the primary/key secondary efficacy endpoints are composite cardiovascular events (e.g., CV death, MI, stroke), not oncological time-to-event outcomes (OS, PFS, DFS, EFS, RFS, TTP). No Kaplan-Meier or HR for an oncology endpoint is presented. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Phase I/II study testing the combination of AGuIX nanoparticles with radiochemotherapy and concomitant temozolomide in patients with newly diagnosed glioblastoma (NANO-GBM trial protocol). PMID 37060055 · BMC Cancer · 2023-Apr-15 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Feasibility and tolerability of sintilimab plus anlotinib as the second-line therapy for patients with advanced biliary tract cancers: An open-label, single-arm, phase II clinical trial. PMID 36444498 · Int J Cancer · 2023-Apr-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Late toxicity comparison of alkylating-based maintenance regimen with cyclophosphamide (VAC) vs ifosfamide (VAI) in Ewing sarcoma survivors treated in the randomized clinical trial Euro-EWING99-R1 in France. PMID 36250317 · Int J Cancer · 2023-Apr-15 The report is a secondary analysis from a randomized trial focusing on late toxicity, with a secondary time-to-event endpoint (10-year EFS) evaluated in a subpopulation of survivors. It is not a primary or definitive efficacy report of the overall trial. Additionally, the trial phase is not explicitly confirmed as Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effectiveness and implementation of mPATH™-CRC: a mobile health system for colorectal cancer screening. PMID 37060023 · Trials · 2023-Apr-14 The record is a protocol for a randomized, non-drug, implementation-effectiveness trial in colorectal cancer screening. It does not meet the core eligibility criteria: it is not a result report, lacks a drug intervention, and does not focus on a time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Nomograms for predicting overall survival and cancer-specific survival in elderly patients with epithelial ovarian cancer. PMID 37059991 · J Ovarian Res · 2023-Apr-14 The record describes a retrospective database analysis (SEER) creating prognostic nomograms for elderly ovarian cancer patients. While it includes randomization (for data splitting) and mentions chemotherapy as a factor, it is not an original report of a Phase III/IIIb or Phase II/III randomized trial of a drug intervention. The 'Randomized Controlled Trial' publication type tag is likely a misclassification. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Predictive value of health-related quality of life on radiotherapy-related toxicities in patients with head and neck cancer. PMID 37058164 · Support Care Cancer · 2023-Apr-14 Study is on head and neck cancer, randomized, and reports a time-to-event toxicity endpoint (hazard ratios from Cox regression). However, it is not a drug-containing intervention trial (radiotherapy is not a drug) and the Phase III status is not confirmed in the provided metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |